
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings Corp is experiencing robust growth, as evidenced by a significant 65% year-over-year increase in its core exome/genome revenue, alongside a consistent rise in average selling prices (ASPs) and testing volumes. The company's strategic shift towards exome and genome-based panels is also notable, projecting a mix shift to 43% of volumes by Q3 2025, supported by an increase in gross margins forecasted to 70%-71%. Furthermore, the positive outlook is corroborated by an upward revision of 2025 revenue guidance to between $425 million and $428 million, highlighting the company's strong positioning in the precision medicine sector.
Bears say
GeneDx Holdings faces a significant cash burn of approximately $2 million per quarter, primarily attributed to challenges associated with its Fabric initiative, which raises concerns about the company’s operational sustainability. Additionally, the high denial rate of 45% for reimbursements from third-party payers, despite being contracted with around 80% of health plans, indicates potential difficulties in achieving future commercial success. Furthermore, disruptions in data and workflow services, coupled with the necessity for a consistent supply of sequencers and materials, pose risks to GeneDx's financial condition and may hinder its growth prospects in the precision medicine sector.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares